Drug intelligence / Profile preview

Tiaogan Jiedu Huashi

Development stage: Unknown
Administration: Oral

Overview

Tiaogan Jiedu Huashi is a traditional Chinese medicine formula that has been investigated for its therapeutic effects in HBeAg-positive chronic hepatitis B patients. It was studied in combination with adefovir dipivoxil to evaluate its impact on hepatitis B e antigen (HBeAg) and HBV-DNA loss, as well as liver function. Clinical trials have shown that this combination therapy can lead to superior HBeAg clearance compared to adefovir dipivoxil monotherapy.

Other names: 调肝解毒化湿颗粒

Beyond the preview

Go deeper on Tiaogan Jiedu Huashi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiaogan Jiedu Huashi.

Explore the full profile